Skip to main content
PMC home page
British Medical Journal (Clinical Research Ed.) logoLink to British Medical Journal (Clinical Research Ed.)
. 1986 Dec 6;293(6560):1459–1462. doi: 10.1136/bmj.293.6560.1459

Persistent HIV antigenaemia and decline of HIV core antibodies associated with transition to AIDS.

J M Lange, D A Paul, H G Huisman, F de Wolf, H van den Berg, R A Coutinho, S A Danner, J van der Noordaa, J Goudsmit
PMCID: PMC1342236  PMID: 3099912

Abstract

Sequential serum samples from 13 homosexual men who seroconverted for antibodies to human immunodeficiency virus (HIV) were tested for HIV antigen. In one of these men, who developed the acquired immune deficiency syndrome (AIDS), HIV antigenaemia preceded the onset of AIDS by more than a year and persisted throughout the course of the disease. This antigenaemia was accompanied by the disappearance of IgG antibody reactivity to the major HIV core protein p24. In none of the 12 others, who all remained without serious disease, were serum concentrations of HIV antigen detected, except on one occasion in one man. All their serum samples showed strong IgG antibody reactivity to p24. Nine children who were infected with HIV in 1981 by plasma transfusion from a single donor were also followed up for HIV antigenaemia. HIV antigen was almost constantly present in the serum (26 of 28 samples) of five children who developed AIDS related complex or AIDS and less often in the serum (four of 10 samples) of four children who remained free of symptoms. The two children who developed AIDS showed a virtual absence of antibody reactivity to p24. These results indicate that increased HIV gene expression is a contributing factor to the development of AIDS and also provide evidence for a switch from latent to active HIV infection.

Full text

PDF
1462

Images in this article

1460FIG 1a
on p.1460
1460FIG 1b
on p.1460
1461FIG 2
on p.1461

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Casey J. M., Kim Y., Andersen P. R., Watson K. F., Fox J. L., Devare S. G. Human T-cell lymphotropic virus type III: immunologic characterization and primary structure analysis of the major internal protein, p24. J Virol. 1985 Aug;55(2):417–423. doi: 10.1128/jvi.55.2.417-423.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Coutinho R. A., Krone W. J., Smit L., Albrecht-van Lent P., van der Noordaa J., Schaesberg W., Goudsmit J. Introduction of lymphadenopathy associated virus or human T lymphotropic virus (LAV/HTLV-III) into the male homosexual community in Amsterdam. Genitourin Med. 1986 Feb;62(1):38–43. doi: 10.1136/sti.62.1.38. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Coutinho R. A., Lelie N., Albrecht-Van Lent P., Reerink-Brongers E. E., Stoutjesdijk L., Dees P., Nivard J., Huisman J., Reesink H. W. Efficacy of a heat inactivated hepatitis B vaccine in male homosexuals: outcome of a placebo controlled double blind trial. Br Med J (Clin Res Ed) 1983 Apr 23;286(6374):1305–1308. doi: 10.1136/bmj.286.6374.1305. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Essex M., Allan J., Kanki P., McLane M. F., Malone G., Kitchen L., Lee T. H. Antigens of human T-lymphotropic virus type III/lymphadenopathy-associated virus. Ann Intern Med. 1985 Nov;103(5):700–703. doi: 10.7326/0003-4819-103-5-700. [DOI] [PubMed] [Google Scholar]
  5. Folks T., Powell D. M., Lightfoote M. M., Benn S., Martin M. A., Fauci A. S. Induction of HTLV-III/LAV from a nonvirus-producing T-cell line: implications for latency. Science. 1986 Feb 7;231(4738):600–602. doi: 10.1126/science.3003906. [DOI] [PubMed] [Google Scholar]
  6. Goedert J. J., Biggar R. J., Weiss S. H., Eyster M. E., Melbye M., Wilson S., Ginzburg H. M., Grossman R. J., DiGioia R. A., Sanchez W. C. Three-year incidence of AIDS in five cohorts of HTLV-III-infected risk group members. Science. 1986 Feb 28;231(4741):992–995. doi: 10.1126/science.3003917. [DOI] [PubMed] [Google Scholar]
  7. Goudsmit J., de Wolf F., Paul D. A., Epstein L. G., Lange J. M., Krone W. J., Speelman H., Wolters E. C., Van der Noordaa J., Oleske J. M. Expression of human immunodeficiency virus antigen (HIV-Ag) in serum and cerebrospinal fluid during acute and chronic infection. Lancet. 1986 Jul 26;2(8500):177–180. doi: 10.1016/s0140-6736(86)92485-2. [DOI] [PubMed] [Google Scholar]
  8. Groopman J. E., Hartzband P. I., Shulman L., Salahuddin S. Z., Sarngadharan M. G., McLane M. F., Essex M., Gallo R. Antibody seronegative human T-lymphotropic virus type III (HTLV-III)-infected patients with acquired immunodeficiency syndrome or related disorders. Blood. 1985 Sep;66(3):742–744. [PubMed] [Google Scholar]
  9. Hardy A. M., Allen J. R., Morgan W. M., Curran J. W. The incidence rate of acquired immunodeficiency syndrome in selected populations. JAMA. 1985 Jan 11;253(2):215–220. [PubMed] [Google Scholar]
  10. Ho D. D., Rota T. R., Schooley R. T., Kaplan J. C., Allan J. D., Groopman J. E., Resnick L., Felsenstein D., Andrews C. A., Hirsch M. S. Isolation of HTLV-III from cerebrospinal fluid and neural tissues of patients with neurologic syndromes related to the acquired immunodeficiency syndrome. N Engl J Med. 1985 Dec 12;313(24):1493–1497. doi: 10.1056/NEJM198512123132401. [DOI] [PubMed] [Google Scholar]
  11. Kalyanaraman V. S., Cabradilla C. D., Getchell J. P., Narayanan R., Braff E. H., Chermann J. C., Barré-Sinoussi F., Montagnier L., Spira T. J., Kaplan J. Antibodies to the core protein of lymphadenopathy-associated virus (LAV) in patients with AIDS. Science. 1984 Jul 20;225(4659):321–323. doi: 10.1126/science.6330889. [DOI] [PubMed] [Google Scholar]
  12. Kitchen L., Malone G., Orgad S., Barin F., Zaizov R., Ramot B., Gazit E., Kreiss J., Leal M., Wichmann I. Viral envelope protein of HTLV-III is the major target antigen for antibodies in hemophiliac patients. J Infect Dis. 1986 Apr;153(4):788–790. doi: 10.1093/infdis/153.4.788. [DOI] [PubMed] [Google Scholar]
  13. Lange J. M., van den Berg H., Dooren L. J., Vossen J. M., Kuis W., Goudsmit J. HTLV-III/LAV infection in nine children infected by a single plasma donor: clinical outcome and recognition patterns of viral proteins. J Infect Dis. 1986 Jul;154(1):171–174. doi: 10.1093/infdis/154.1.171. [DOI] [PubMed] [Google Scholar]
  14. Melbye M., Biggar R. J., Ebbesen P., Neuland C., Goedert J. J., Faber V., Lorenzen I., Skinhøj P., Gallo R. C., Blattner W. A. Long-term seropositivity for human T-lymphotropic virus type III in homosexual men without the acquired immunodeficiency syndrome: development of immunologic and clinical abnormalities. A longitudinal study. Ann Intern Med. 1986 Apr;104(4):496–500. doi: 10.7326/0003-4819-104-4-496. [DOI] [PubMed] [Google Scholar]
  15. Schüpbach J., Haller O., Vogt M., Lüthy R., Joller H., Oelz O., Popovic M., Sarngadharan M. G., Gallo R. C. Antibodies to HTLV-III in Swiss patients with AIDS and pre-AIDS and in groups at risk for AIDS. N Engl J Med. 1985 Jan 31;312(5):265–270. doi: 10.1056/NEJM198501313120502. [DOI] [PubMed] [Google Scholar]
  16. Steimer K. S., Higgins K. W., Powers M. A., Stephans J. C., Gyenes A., George-Nascimento C., Luciw P. A., Barr P. J., Hallewell R. A., Sanchez-Pescador R. Recombinant polypeptide from the endonuclease region of the acquired immune deficiency syndrome retrovirus polymerase (pol) gene detects serum antibodies in most infected individuals. J Virol. 1986 Apr;58(1):9–16. doi: 10.1128/jvi.58.1.9-16.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Wong-Staal F., Gallo R. C. Human T-lymphotropic retroviruses. Nature. 1985 Oct 3;317(6036):395–403. doi: 10.1038/317395a0. [DOI] [PubMed] [Google Scholar]
  18. di Marzo Veronese F., Copeland T. D., DeVico A. L., Rahman R., Oroszlan S., Gallo R. C., Sarngadharan M. G. Characterization of highly immunogenic p66/p51 as the reverse transcriptase of HTLV-III/LAV. Science. 1986 Mar 14;231(4743):1289–1291. doi: 10.1126/science.2418504. [DOI] [PubMed] [Google Scholar]

Articles from British Medical Journal (Clinical research ed.) are provided here courtesy of BMJ Publishing Group

RESOURCES